Disclosures for "Effectiveness and Optimization of Low-Sodium Oxybate in Participants With Narcolepsy Switching From High-Sodium Oxybate: Interim Data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study")
-
Eileen Leary has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Eileen Leary has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Proper. Eileen Leary has stock in Jazz Pharmaceuticals.
-
Dr. Kirby has received personal compensation for serving as an employee of Jazz Pharmaceuticals, Inc. Dr. Kirby has stock in Jazz Pharmaceuticals, Inc..
-
Dr. Skowronski has nothing to disclose.
-
Mr. Xu has received personal compensation for serving as an employee of Jazz Pharmaceuticals Inc.
-
Mr. Pfister has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Pfister has stock in Jazz Pharmaceuticals.
-
Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has received stock or an ownership interest from Jazz pharma.